Now with these positive data in hand, we are focused on our NDA submission to the FDA expected in the third quarter of 2026" (President, CEO & Director Mortimer). "Our base case assumption is a ...

Liam Flin assesses the Europa League final markets ahead of the showpiece between Freiburg and Aston Villa in Istanbul on May ...

Positive topline Phase 1 data for BGE-102, demonstrating potential best-in-class reductions among oral NLRP3 inhibitors in inflammatory biomarkers of cardiovascular risk ...

Trump cited the War Powers Resolution to declare the Iran conflict over, but Iranian attacks on U.S. ships during Project ...

NewAmsterdam Pharma (NASDAQ:NAMS) said it plans to conduct an interim analysis of its ongoing PREVAIL cardiovascular outcomes trial (CVOT) for obicetrapib in the fourth quarter of 2026, citing what ex ...

US lawmakers challenge FIFA's 'opaque' dynamic pricing. Are fans facing artificial scarcity? Discover the tactics and the ...

Initial CX-801 clinical data in advanced melanoma, both as monotherapy and in combination with KEYTRUDA, are expected by the end of 2026, with observed tolerability at doses surpassing the approved ...

California families welcoming newborns will soon receive hundreds of free diapers before leaving the hospital under a ...

Codexis outlined ongoing commercial discussions supported by a "very, very healthy" sales funnel spanning large pharma, ...

Q1 2026 Earnings Call May 7, 2026 4:30 PM EDTCompany ParticipantsPedro Malha - CEO, President & DirectorMichael Monahan ...

Crystal Palace are odds-on favourites to win the Conference League against Rayo Vallecano, with both teams seeking a first ...

Q1 2026 Management View "As we communicated on our last earnings call, we expect that 2026 will be a transition year with revenue primarily driven by consumable utilization from our installed base and ...